محتوى الدورة
Certara.R School - Lesson 12: History and Advantages of the PML Language Pinnacle 21 Enterprise Unlocking Efficiency and Quality: What is New in Phoenix™️ 8.4? What’s New for SEND 2023 Webinar AI in Healthcare Today – Dell Technologies & Certara Vyasa Layar Explainer Certara SEND Webinar Series Session #1 FDA Modernization Act 2.0 – What does it mean for drug developers? D360 as your organization’s extendable and central data engine Machine learning model selection with Darwin in Pirana Learn how Certara’s Integral streamlines PK/PD workflows Learn how to leverage the power of cloud computing to streamline your workflow! Learn how to create CDISC domains in minutes with PK Submit How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing Learn how to leverage the power of cloud computing to streamline your workflow! Phoenix WinNonlin Secure Learn how to shorten the drug discovery design-make-test-analyze cycle with D360 Learn how to save valuable time on PK/PD analysis and modeling with Certara’s Phoenix Platform Learn how to streamline PK/PD workflows with Certara’s Integral Data Repository Learn why Phoenix is the industry gold standard for PK/PD analysis eChalk Talk: How Oncology Drug Developers Can Prepare for FDA’s Project Optimus BaseCase Video Control Demo Learn how Integral streamlines PK/PD workflows & ensures compliance with regulatory requirements 1. Phoenix Screen Resolution Improved Workflow and Expanded Functionality of RsNLME - Version 1 What Oncology Drug Developers Should Expect from the FDA’s Project Optimus Predicting and Taming Immunogenicity: Overview of Immunogenicity & ADA Assays Predicting and Taming Immunogenicity: What is an Integrated Summary of Immunogenicity (ISI)? Predicting and Taming Immunogenicity: Complex Biologic Considerations Best Practices in Data Programming: A Chat with Susan Potts The TOGETHER Study Shows that Fluvoxamine Reduces Risk of Prolonged Hospitalization Predicting and Taming Immunogenicity: Strategies for your Biologic Drug Learn How Discovery Data Technology Enables Faster Discovery Research New Horizons in Pediatric Drug Development - Day 2, Session 2 - Panel Discussion New Horizons in Pediatric Drug Development - Day 2, Session 3 New Horizons in Pediatric Drug Development - Day 2, Session 3 - Panel Discussion New Horizons in Pediatric Drug Development - Day 2, Session 3 New Horizons in Pediatric Drug Development - Day 2, Session 3 New Horizons in Pediatric Drug Development - Day 2, Session 2 New Horizons in Pediatric Drug Development - Day 2, Session 2 New Horizons in Pediatric Drug Development - Day 2, Session 2 New Horizons in Pediatric Drug Development - Day 2, Session 1 - Panel Discussion New Horizons in Pediatric Drug Development - Day 2, Session 1 New Horizons in Pediatric Drug Development - Day 2, Session 1 New Horizons in Pediatric Drug Development - Day 2 - Opening Remarks New Horizons in Pediatric Drug Development - Day 1, Session 2 - Panel Discussion New Horizons in Pediatric Drug Development - Day 1, Session 2, Part 2 New Horizons in Pediatric Drug Development - Day 1, Session 2, Part 1 New Horizons in Pediatric Drug Development - Day 1, Session 2 - Panel Discussion New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 2 New Horizons in Pediatric Drug Development - Day 1, Session 1, Part 1 New Horizons in Pediatric Drug Development - Day 1 Q&A New Horizons in Pediatric Drug Development - Keynote New Horizons in Pediatric Drug Development - Day 1 - Introduction & Welcome Better Together: An Interview with Patrick Smith, Raj Bhardwaj, and Mayumi Hasegawa What does the Clin Pharm Plan for a Biologic Look Like? Pharmacometrics & Clinical Pharmacology FOMO: Why the Future of Research is in Africa When you have a spot, get your spot! Your First Choice in Complex Biologics Drug Development The Wizard of Oligos: There’s no place like having a successful drug development program! The Promises and Pitfalls of Gene Therapy for Rare Diseases Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors Best Practices for oligonucleotide therapeutic development: Q&A Oligonucleotide therapeutic development: Clinical pharmacology considerations Oligonucleotide therapeutic development: Pre-clinical and translational considerations What are oligonucleotide therapeutics, and how do they work? Expert Tips for Pediatric Drug Development and Regulatory Success Getting the Dose Right for COVID-19 Vaccines Submerge in the Oligonucleotide Emerge: Best Practices for Developing These Complex Biologics How to Accelerate COVID-19 Vaccine Development with Biosimulation Enhance Your Drug Development Capacity with Clin Pharm Study Execution & Operational Support Model-based meta-analysis for comparative efficacy and safety of therapeutics for COVID-19 Making your drug program investor-ready Avoid these common mistakes to secure a deal An Introduction to Asset Evaluation The Role of MIDD in Drug Development for COVID-19 Juvenile toxicity studies considerations – not just “mini” general tox! Supporting the global approval of an antiviral drug for infants Intro to Smart In Silico Tools to Aid in Translating In Vitro & In Vivo Studies Accelerating Medicines & Vaccines Using Virtual Patients Solving a Mystery Using PBPK: How Drug-excipient Complexes Can Confound a Metabolic DDI Result CODEx Demo Fostering Pediatric Oncology Drug Development Accelerating Therapeutics for COVID-19: Dr. Craig Rayner D360 Overview Accelerating Vaccine Development: Applications to COVID-19 and Future Pandemics HIV Déjà Vu? Optimizing Cocktail Therapies for COVID-19 COVID-19 Therapeutic Considerations for Children and Pregnant Women Team Certara - Let's Beat COVID Together Pharmacology to Payer: One Quantitative Drug Development Framework to Rule Them All Using PK/PD M&S for Pediatric Drug Development: Regulatory Insights into Practical Issues Found in Translation Building an Early Development Strategy for Complex Biologics How Due Diligence Facilitates Successful Biotech Investments, Deals, and Partnerships Application of Tracer Kinetics in Drug Development A Valuable but Underused Tool in Clinical Pharmac A House Divided – The Interplay of Bioanalysis and Pharmacokinetics Apocalyptic Clinical Pharmacology A Comprehensive Approach to Drug Development Value Focused MIDD: Influenza Model-informed Drug Development Program Value Focused MIDD: Respiratory Syncytial Virus (RSV) Model-informed Drug Development Program Value Focused MIDD: Oncology Model-informed Drug Development Program Town Level Agent Based Influenza Model Influenza pandemic model of US Best Practices in Clinical Pharmacology Gap Analysis

للحصول على شهادة

  • 1- التسجيل
  • 2- مشاهدة الكورس كاملا
  • 3- متابعة نسبة اكتمال الكورس تدريجيا
  • 4- بعد الانتهاء تظهر الشهادة في الملف الشخصي الخاص بك